{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123303","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.882440+00:00","generated_at":"2026-05-30T03:18:57.477980+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cardiff Oncology Q3 cash $57.7M; initial CRDF-004 data expected by year-end","bullets":["Cash, equivalents, and short-term investments of $57.7M as of Sept 30, 2024.","Net cash used in operations: $10.5M in Q3 2024, up from $8.0M in Q3 2023.","Total operating expenses $12.8M for Q3 2024, an increase of $1.8M YoY.","Initial data readout from first-line RAS-mutated mCRC CRDF-004 trial expected by end of 2024.","Phase 2 trial in second-line KRAS-mutant mCRC published in Journal of Clinical Oncology; bev naïve patients had ORR 77% and mPFS 14.9 months."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123303","json":"https://secwatch.observer/filing/0000950170-24-123303.json","markdown":"https://secwatch.observer/filing/0000950170-24-123303.md","text":"https://secwatch.observer/filing/0000950170-24-123303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000095017024123303/0000950170-24-123303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000095017024123303/crdf-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:18:57.477980+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}